Biformyx BioPharma
- | Biotech or pharma, therapeutic R&D
BiFormyx is an innovative biopharmaceutical company with a suite of novel dual-payload, antibody-drug conjugates (ADCs) for cancer. Our best-in-class lead asset is a humanized B7-H3 monoclonal antibody with dual drug payloads (a cytotoxic agent and immune stimulating agent) targeting Triple Negative Breast Cancer (TNBC). The dual payload provides a ‘2-punch’ mechanism of action against TNBC, and we are initiating IND-enabling studies for this indication. Beyond this asset, our proprietary dual-linker technology, which allows variable drug-drug and drug-antibody ratios, can be applied to any monoclonal antibody and an array of therapeutic payloads. As a result, we are building a robust pipeline to address multiple oncology indications.
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}